Abbott's Take on Emerging Markets

February 12, 2016

1 Min Read
How Are Medtech's Emerging Markets Faring?—Abbott

Abbott's Take on Emerging Markets

"Every morning we get up, we see CNBC. Everybody brings their hands about China, but whether China is 7% growth or 6% growth, 6% is way bigger than the rest of the world. It's a fundamentally strong market for us as [are] practically all of these emerging markets.

Now, the oil-based economy, the ones we were extremely dependent on oil, take Venezuela--okay, there are different stories. And the volatility, unreliability and sustainable market there is different than just about anywhere in the world . . . 

. . .  As many of you know, market conditions in Venezuela have become more challenging including high inflation, increasing price and margin controls, regulations on import, and slowing demand.

As a result, our forecast assumes a significantly lower contribution from Venezuela operation in 2016."

Miles White, Abbott chairman and CEO, according to a Seeking Alpha transcript of the company's fourth quarter earnings call

             

Get inspired to innovate during Massachusetts Medtech Week--register for BIOMEDevice Boston 2016, April 13-14.

[Image courtesy of TUOMAS-LEHTINEN/FREEDIGITALPHOTOS.NET]  

Sign up for the QMED & MD+DI Daily newsletter.

You May Also Like